

β-hCG Immunoreactivity in Human Cervical Carcinoma

SERVİKS KANSERİNDE p-hCG İMMÜNREAKTİVİTESİ

Dr.Turhan USLU*, Prof.Dr.Hikmet YAVUZ", Doç.Dr.Feride SÖYLEMEZ**,
Prof.Dr.Sevgi TEZCAN, Dr.Alev USLU***

* From the Ministry of Health, Zübeyde Hanım Maternity Hospital, ANKARA

** Department of Gynecology-Obstetrics, Faculty of Medicine, University of Ankara

*** From the Ministry of Health, Ankara Hospital, ANKARA

SUMMARY

Cervical carcinoma was investigated for immunoreactivity of p-hCG. 25 patients with cervical cancer in various stages were examined from this point of view. In this preliminary report the overall immunoreactivity of p-hCG was found to be 40 per cent. The values found were between 2 and 50 mIU/ml and there was no significant correlation between age and the p-hCG values ($r=0.3113$, $p>0.05$). Additionally, results from the patients undergoing various treatment modalities were not differ from each other significantly ($X^2=1.3972$, $0.3>0.3>p>0.2$).

Key Words: Cervical carcinoma, p-hCG immunoreactivity

Anatolian J Gynecol Obst 1992, 2:260-262

Human chorionic gonadotropin (hCG) may be secreted by several tumors ectopically. The incidence of ectopic hCG secretion ranges between 17 and 56 per cent among these tumors (1,2,3). hCG is composed of two noncovalently linked subunits designated a and p. Low concentrations of a hCG like substance have been reported in all tumors described (4). However other investigators have not confirmed these observations. Ectopic productions of placental proteins by human cancer are of particular interest because of the similarities between neoplastic and embryonic cells. In this preliminary report, we demonstrate that immunoreactive p hCG are secreted by the patients with cervical carcinoma.

Geliş Tarihi: 29.1.1991

Kabul Tarihi: 5.2.1992

Yazışma Adresi: Dr.Turhan USLU

Sedat Simavi Sokak 37/20
06540 Çankaya - ANKARA

% It was presented at "Jinekoloji Onkolojide Diagnostik ve Terapötik Yaklaşımlar Kongresi, I. Uluslararası Kolposkopi ve Laser Kursu 26-28 Eylül 1991 Falez Otel - ANTALYA"

260

ÖZET

Serviks karsinomunun, p-hCG immünreaktivitesi araştırılmıştır. Yapılan bu ön çalışmada değişik evrelerde 25 serviks kanserli hasta bu açıdan incelenmiştir. Tüm gruptaki p-hCG immünreaktivitesi %40 olarak bulunmuştur. Serum değerleri 2 ile 50 mIU/ml arasında dağılım göstermiştir. Yaş ve p-hCG seviyeleri arasında belirgin bir korelasyon kurulamamıştır ($r=0.3113$, $p>0.05$). Ayrıca değişik tedavi şekilleri uygulanan hasta grupları arasında anlamlı bir fark gözlenememiştir ($X^2=1.3972$, $0.3>0.3>p>0.2$).

Anahtar Kelimeler: Serviks kanseri p-hCG immünreaktivitesi

T Klin Jinekoloji Obst 1992, 2:260-262

MATERIALS AND METHODS

Patients

A total of 25 patients with cervical carcinoma were studied. Cervical carcinoma was staged according to the classification recommended by the International Federation of Gynecology and Obstetrics (FIGO). Serum samples were taken during the treatment in all cases. Samples were obtained from 7 patients within the first week of radical surgery and from 18 patients during radio-and/or chemotherapy.

hCG assay

We used "Amerlex-M Beta hCG RIA kit" (Amersham) for hCG p subunit. Serum specimens were stored at -20°C . Before performing the assay all specimens were mixed thoroughly until they reached the room temperature. Radioimmunoassays for p-hCG were performed by the double antibody procedure (5,6). The method depends on competition between hCG in the sample and ^{125}I -labeled hCG present, antibody bound hCG is reacted with the Amerlex-M second antibody reagent which contains second antibody that is bound

T Klin Jinekoloji Obst 1992, 2

to magnetic polymer particles. According to this kit values 10 mIU/ml were accepted positive.

We performed regression analysis in order to find any relation between the age of the patient and the assays. Also Chi-square test (Fourfold table-Yates correction) was performed to show the significance of the therapy.

RESULTS

The distribution of values according to the stages of cervical carcinoma were expressed graphically (Figure 1). The elevated serum p hCG concentrations varied between 2 and 50 mill/ml second International standart (2nd IS). 40 per cent of the patients shower immunoreactivity in the overall group. There was no significant correlation between the ages of the patients and the p-hCG values ($r=0.3113$, $p>0.05$). When the results are examined, there is also no significant change on (β-hCG secretion whether the disease has been cured or not (Table 1).

DISCUSSION

Ectopic production of hCG is not uncommon (1,7,8,9) and small amounts of free hCG p subunit may be found in the serum of patients with some non-trophoblastic tumors. This report documents the example In vivo of ectopic production of free p subunit of chorionic gonadotropin.

All human tissues appear to make hCG as a whole molecule, but placenta is different in having the ability to glycosylate the protein thus reducing its rate of metabolism and giving it biological activity through a long half life (10). In addition, cell lines derived from non-trophoblastic tumors also produce hCG, a-hCG, p-hCG (5,6,11,12).




Figure 1. Distribution of β-hCG according to the stages of cervical carcinoma.

Table 1. Results of the patients undergoing various treatment modalities

β-hCG Therapy	n		Total
	β-hCG >10mIU/ml	β-hCG < mIU/ml	
Surgical therapy	2	5	7
Radio-and/or			
Chemotherapy	8	10	18
Total	10	15	25

$X^2 - 1.3972$, $0.3 > p > 0.2$

HCG is one of the embryonic gene products appearing in ontogeny. The finding of circulating hCG in association with malignant neoplasms has been regarded generally as another expression of embryonic antigens in cancer. The origin of this hCG activity is not known. Among unselected patients with various neoplasms it was found that hCG positive patients were older than hCG negative patients (8). But in our study, we found no significant correlation between the age and the p hCG values of the patients ($r=0.3131$, $p>0.05$). Even though the patients who had surgical therapy do not show any trace of cancer, the hCG values have been found positive in 28.6% of the patients. Similarly, 44.4% of the patients who had radio-and/or chemotherapy and who showed no clinical symptoms had positive hCG values.

CONCLUSION

Patients with tumors which secrete gonadotropins ectopically are not recognized by clinical syndromes attributed to excessive gonadotropin secretion because resulting gonadotropin excess usually is not manifested clinically. In conclusion we can say that the frequency and types of tumors associated with hCG production are greater than previously appreciated. While very low levels occur in cervical carcinoma utilizing the hCG p subunit for monitoring the course of the disease does not seem promising.

REFERENCES

1. Baunstein GD, Vaitukaitis JI, Carbone PP, Ross GT. Ectopic production of human chorionic gonadotropin by neoplasms. *Annals of Internal Medicine* 1973; 78:39.
2. Lange PH, McInitre KR, Waldmann TA. Serum alpha-feto-protein and human chorionic gonadotropin in the diagnosis and management of nonseminomaous germ cell testicular cancer. *N Engl J Med* 1976; 295:1237.
3. Nagelberg SM, Marmorstein B, Khazaeli MB, Rosen SW. Isolated ectopic production of the beta subunit of chorionic gonadotropin by epidermoid carcinoma of unknown primary site. *Cancer* 1985; 55:1924.

4. Odeh WA, Wolisen Y, Yoshimoto R, Weitzman D, Hirose F. Ectopic peptide synthesis: A universal concomitant of neoplasia. *Trans Assoc Am Physicians* 1977; 90:204.
8. Coie LA, Hussa RO, Rao CV. Discordant synthesis and secretion of human chorionic gonadotropin and subunits by cervical carcinoma cells. *Cancer Research* 1981; 41:1615.
6. Story MI, Hussa HO. Ectopic secretion of complete human chorionic gonadotropin and beta-subunit by human cervical carcinoma cell lines. *J Clin Endocrinol Metab* 1980; 50:1057.
7. Das S, Mukherjee K, Bhattacharya S, Chowdhury JRA. A comparative study of ectopic production of human chorionic gonadotropin and human chorionic somatomammotropin by carcinoma of the uterine cervix. *Oncology* 1984; 41:303.
8. Rutanen EM, Seppala M. The hCG-beta subunit radioimmunoassay in non-trophoblastic gynecologic tumors. *Cancer* 1978; 41:692.
9. Shetty NA, Aclii MA, Nadkarni J J, Rujpal R M, Shelf AR. Intact human placental lactogen and beta subunit of human chorionic gonadotropin by cancer of the cervix. *J Clin Endocrinol* 1981; 11:324.
10. Speroff L, Glass RH, Kase NG. *Hormone Biosynthesis, Metabolism and Mechanism of action: Clinical Gynecologic Endocrinology and Infertility*. Fourth Edition. Baltimore, Williams and Wilkins 1989; 31-46.
11. Hussa RO, Fein HG, Patil RA, Nagelberg SB, Rosen SVV, Weirtraub BD, Perini F, Rudson RW, Cole LA. A distinctive form of human chorionic gonadotropin beta-subunit-like material produced by cervical carcinoma cells. *Cancer Research* 1986; 46:1948.
12. Rudson RW, Hanson OA, Bryan AH, Putterman GJ, While L, Perini F, Meade KS, Awenferder PH. Synthesis and secretion of human chorionic gonadotropin subunits by cultured human malignant cells. *J Biol Chem* 1980; 255:1000.